PDF(Pubmed)
Abstract：
Juvenile idiopathic arthritis (JIA) is the most frequent rheumatic disease of childhood and uveitis is its most common extra-articular manifestation. JIA-associated uveitis (JIA-U) is one of the main causes of visual impairment in children and represents a major challenge for pediatrician and ophthalmologist, due to its insidious onset and sight-threatening complications. Topical glucocorticoids are the first line of treatment, followed by conventional disease-modifying anti-rheumatic drugs (DMARDs), usually methotrexate (MTX). In recent years, new biological drugs targeting specific molecules involved in disease pathogenesis, have significantly improved the prognosis of the disease, especially for cases refractory to conventional therapies. In this review we discuss the role of biological agents in JIA-U, focusing on cytokine blockers and cell-targeted therapies aimed to control ocular inflammation.
摘要：
幼年特发性关节炎（JIA）是儿童时期最常见的风湿性疾病，葡萄膜炎是其最常见的关节外表现。JIA相关葡萄膜炎（JIA-U）是儿童视力障碍的主要原因之一，对儿科医生和眼科医生来说是一个重大挑战。由于其隐匿的发作和危及视力的并发症。外用糖皮质激素是一线治疗，其次是传统的疾病缓解抗风湿药（DMARDs），通常甲氨蝶呤（MTX）。近年来,靶向参与疾病发病机制的特定分子的新型生物药物，显著改善了疾病的预后，尤其是常规疗法难以治疗的病例。在这篇综述中，我们讨论了生物制剂在JIA-U中的作用，重点关注细胞因子阻断剂和旨在控制眼部炎症的细胞靶向治疗。
